Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir

• Main Authors: Bandar Alosaimi (Author), Huda M. Alshanbari (Author), Muath Alturaiqy (Author), Halah Z. AlRawi (Author), Saad Alamri (Author), Asma Albujaidy (Author), Aljawharah Bin Sabaan (Author), Ahmed A. Alrashed (Author), Ahmad Alamer (Author), Fayez Alghofaili (Author), Khaled Al-Duraymih (Author), Abdulaziz J. Alshalani (Author), Wael Alturaiki (Author)
• Formato: Livro
• Publicado em: MDPI AG, 2022-11-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

<i>Background</i>: The coronavirus 2019 (COVID-19) disease, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus led to a global pandemic. HCQ and FPV were used early in the pandemic as a treatment modality for COVID-19. Various studies evaluated the HCQ and F...